Gene Transfer, Dose-Finding Safety, Tolerability, and Efficacy Study of SPK-8011 [a Recombinant Adeno-Associated Viral Vector With Human Factor VIII Gene] in Individuals With Hemophilia A

Trial Profile

Gene Transfer, Dose-Finding Safety, Tolerability, and Efficacy Study of SPK-8011 [a Recombinant Adeno-Associated Viral Vector With Human Factor VIII Gene] in Individuals With Hemophilia A

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs SPK 8011 (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Spark Therapeutics
  • Most Recent Events

    • 11 Dec 2017 Results presented in a Spark Therapeutics media release.
    • 11 Dec 2017 According to a Spark Therapeutics media release, preliminary data from this trial was presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 05 Dec 2017 According to a Spark Therapeutics media release, preliminary results from this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition (2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top